<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03884491</url>
  </required_header>
  <id_info>
    <org_study_id>18026A</org_study_id>
    <nct_id>NCT03884491</nct_id>
  </id_info>
  <brief_title>A Study Investigating Formulations of Vortioxetine Applied Under the Tongue in Healthy Subjects</brief_title>
  <official_title>Interventional, Open-label, Sequential-period Study Investigating the Pharmacokinetic Properties and Safety and Tolerability of Sublingual Formulations of Vortioxetine in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates formulations of vortioxetine applied under the tongue
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Apart from the first two doses, the study design is flexible in terms of doses and
      pharmaceutical formulations and will be decided upon based on an evaluation of the safety and
      tolerability as well as plasma exposure obtained during the study.

        -  The study consists of 5 periods. Single-doses of vortioxetine will be administered in
           all periods.

        -  All subjects will receive the same pharmaceutical formulations of the same dose strength
           in the same period and sequence.

        -  In Period 1, each subject will receive an intravenous (IV) 10 mg dose of vortioxetine
           infused over 2 hours. The exposure obtained after IV administration will serve as the
           reference for the sublingually administered dosage forms.

        -  In Period 2, each subject will receive 5 mg of formulation A (SLA) of vortioxetine in a
           sublingual (SL) formulation with a holding time of 90 seconds. The holding time is the
           time where swallowing of saliva should be avoided.

        -  For the 3 remaining dosing periods, one or more of the following options in
           pharmaceutical formulation, dose, and dosing condition apply to this study:

             -  Increases or decreases in dose (≤25mg) using same formulation

             -  Change from formulation SLA to formulation SLB

             -  Change in the holding time

             -  Change to formulation SLC

             -  Change in swallowing technique of the sublingual dosage forms
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 18, 2019</start_date>
  <completion_date type="Actual">July 22, 2019</completion_date>
  <primary_completion_date type="Actual">June 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>absolute bioavailability (F)</measure>
    <time_frame>From predose to 72 hours post dose</time_frame>
    <description>absolute bioavailability of vortioxetine for the sublingual administrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax</measure>
    <time_frame>From predose to 72 hours post dose</time_frame>
    <description>time to maximum plasma concentration (tmax)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Vortioxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine IV</intervention_name>
    <description>an intravenous (IV) 10 mg dose (1 mg/mL) of vortioxetine infused over 2 hours</description>
    <arm_group_label>Vortioxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine SLA</intervention_name>
    <description>5-25 mg of sublingual formulation A of vortioxetine</description>
    <arm_group_label>Vortioxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine SLB</intervention_name>
    <description>5-25 mg of sublingual formulation B of vortioxetine</description>
    <arm_group_label>Vortioxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine SLC</intervention_name>
    <description>formulation SLC: solution of vortioxetine, concentrate (12.5 mg/mL-62,5 mg/mL) 200 uL or 400 uL, SL, 5-25 mg</description>
    <arm_group_label>Vortioxetine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -The subject has a BMI ≥18.5 and ≤30.0 kg/m2 at the Screening Visit and at the Baseline
        Visit.

        Exclusion Criteria:

        -The subject is identified or confirmed to be a CYP2D6 poor metabolizer (PM)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Sciences Ltd</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>July 30, 2019</last_update_submitted>
  <last_update_submitted_qc>July 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vortioxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

